TBL1X is highly expressed in MCL, and high TBL1X expression is associated with poorer prognosis in patients with MCL. Immunoblot analyses for TBL1X expression in (A) MCL cell lines (n = 9) and (B) primary MCL patient samples (n = 10) of variable genetic backgrounds, as compared with normal B cells. (C) Comparison of relative TBL1X transcript levels (ΔΔCT) in normal B cells (n = 10) compared with MCL samples from patients with MCL (n = 36). (D) OS for patients with MCL (n = 33) having the highest (top 33%) and lowest (bottom 33%) levels of TBL1X expression (TBL1X^High [n = 19] and TBL1X^Low [n = 14], respectively) depicted by Kaplan-Meier plot and analyzed with the log-rank Mantel-Cox test. Median OS for patients with MCL with high TBL1X expression was 21.37 vs 31.38 months for those with low expression (P = .0405; hazard ratio = 2.8). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.